Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Extended Azithromycin Treatment in Prelabor Rupture of Membranes

21. Juni 2026 aktualisiert von: Alexa Henderson

Extended Azithromycin Treatment in Peri-viable and Extremely Preterm Prelabor Rupture of Membranes: A Pilot Study

The purpose of this study is to learn whether adding extra doses of azithromycin to the standard antibiotic treatment for preterm prelabor rupture of membranes may improve pregnancy outcomes for patients between 22 weeks and 28 weeks gestational age.

Researchers will compare the standard antibiotic treatment to the standard antibiotic treatment with additional doses of azithromycin.

Participants will:

  • Be randomly assigned to one of two groups:
  • The standard antibiotic treatment
  • The standard antibiotic treatment plus 7 additional doses of oral azithromycin 500 mg every other day.
  • Participants will be asked to complete a survey regarding their experience and side effects.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Multiple randomized trials have shown that antibiotic treatment for preterm prelabor rupture of membranes (PPROM) increases pregnancy latency and decreases maternal and neonatal morbidity. However, the optimal dosing schedule for azithromycin in PPROM is not fully understood. This pilot study will assess the feasibility of a non-blinded, randomized-controlled trial comparing maternal and neonatal outcomes between the standard PPROM antibiotic regimen and the standard regimen with extended azithromycin therapy in participants with periviable and extremely preterm PPROM between 22- and 28-weeks gestational age. Preliminary data on pregnancy latency, maternal morbidity, and neonatal outcomes will also be collected. Findings from this feasibility study will inform the design of a future, powered study.

The investigators hypothesize that extended azithromycin therapy may be associated with longer pregnancy latency and decreased rates of maternal and neonatal morbidity compared to standard therapy. This hypothesis is exploratory, and the present feasibility study is not powered to test a hypothesis.

The primary objective is to evaluate the feasibility of conducting a non-blinded, randomized controlled trial of extended azithromycin therapy in participants with periviable and extremely preterm prelabor rupture of membranes (PPROM) who desire expectant management between 22 and 28 weeks gestational age. Specifically, we aim to assess feasibility metrics including recruitment and consent rates, randomization procedures, adherence to the study protocol, and completeness of follow-up.

The secondary objectives of this pilot study are to estimate the variability (standard deviation) of pregnancy latency in this population to inform sample-size calculations for a future definitive trial. The investigators will also collect preliminary data on maternal outcomes (e.g., rates of intra-amniotic infection, endometritis, and placental abruption) and neonatal outcomes (gestational age at delivery, NICU admission, morbidity) for planning purposes. Additionally, the investigators will review placental pathology reports to identify the stage/grade of chorioamnionitis per the Amsterdam criteria. The investigators will obtain an initial estimate of the effect of extended azithromycin on pregnancy latency, recognizing that this pilot study is not powered to detect clinically meaningful differences.

Studientyp

Interventionell

Einschreibung (Geschätzt)

30

Phase

  • Phase 4

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

  • Vereinigte Staaten
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15217
        • University of Pittsburgh Magee-Womens Hospital
        • Kontakt:
        • Kontakt:
        • Hauptermittler:
          • Christina Megli, MD, PhD
        • Unterermittler:
          • Alexa Henderson, MD

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Singleton gestation
  • Gestational age at time of PPROM between 22w0d and 28w0d
  • Opting for expectant management in the inpatient setting after completion of a maternal-fetal medicine and neonatology consultation (per standard of care)
  • Remain pregnant 48 hours after presentation.
  • Patients who receive betamethasone, magnesium therapy, and/or a limited course of tocolysis (through the betamethasone window) will be included.
  • Pregnant patients below the age of 18 are eligible.

Exclusion Criteria:

  • Contraindications to expectant management (clinical intra-amniotic infection, active preterm labor, or acute placental abruption)
  • Lethal congenital defects
  • Multiple gestation
  • Ongoing alternative antibiotic treatment
  • Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic
  • History of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin
  • Known prolongation of QT interval
  • History of torsades de pointes
  • Congenital long QT syndrome
  • Bradyarrhythmia
  • Decompensated heart failure
  • Drugs known to significantly prolong the QT interval including Class 1A and Class III antiarrhythmic agents
  • Impaired hepatic function
  • GFR<10 mL/min
  • Diagnosis of myasthenia gravis

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Standard Antibiotic Regimen
A single dose of oral azithromycin 1 gram which is given at the time of presentation in addition to the standard intravenous ampicillin 2g q6h for 48 hours followed by oral amoxicillin 250 mg q8 hours for 5 days.
Arzneimittel: Standard Azithromycin Dosing
Oral Azithromycin 1g once.
Experimental: Extended Azithromycin Regimen
The standard antibiotic regimen will be given in addition to Azithromycin 500g every other day for 7 additional doses.
Arzneimittel: Standard Azithromycin Dosing
Oral Azithromycin 1g once.
Arzneimittel: Azithromycin (Azithro)
Azithromycin 500 mg every other day for 7 additional doses will be given in addition to the standard antibiotic regimen.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Recruitment Capability
Zeitfenster: From recruitment to enrollment, up to 3 days.
Number of participants recruited per week/month
From recruitment to enrollment, up to 3 days.
Participant Eligibility
Zeitfenster: From recruitment until enrollment, up to 3 days.
Percentage of eligible participants who agree to participate, reasons for refusal or ineligibility
From recruitment until enrollment, up to 3 days.
Retention and Dropout Rates
Zeitfenster: From recruitment to completion of the study, up to 4 months.
Percentage of patients who complete study and reasons for withdrawal from study.
From recruitment to completion of the study, up to 4 months.
Intervention Delivery
Zeitfenster: From recruitment to completion of intervention, up to 15 days.
Percentage of interventions delivered as intended
From recruitment to completion of intervention, up to 15 days.
Participant Acceptability
Zeitfenster: At completion of study (either after Day 14 of study or after delivery if does not complete study) prior to hospital discharge.
Likert-scale survey evaluating the participant's perceived affective attitude, burden, ethicality, intervention coherence, confidence, opportunity costs, general acceptability, and side effects related to the study.
At completion of study (either after Day 14 of study or after delivery if does not complete study) prior to hospital discharge.
Data Collection Procedures
Zeitfenster: From recruitment to completion of postpartum period, up to 6 months.
Data completeness measured as number of participants with complete data entry.
From recruitment to completion of postpartum period, up to 6 months.
Resource Use and Cost
Zeitfenster: From recruitment to postpartum period, up to 6 months.
Total cost versus planned budget, time and staffing required.
From recruitment to postpartum period, up to 6 months.
Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
Zeitfenster: Ongoing during treatment from Day 2 through Day 14. Formally assessed with surveys as above on Day 8 and Day 14 (or earlier if delivers prior to completion of study period).
Adverse events associated with antibiotic usage, maternal and neonatal outcomes, bacterial resistance profiles. Assessed using previously validated Medication Side Effect survey.
Ongoing during treatment from Day 2 through Day 14. Formally assessed with surveys as above on Day 8 and Day 14 (or earlier if delivers prior to completion of study period).
Protocol Deviations
Zeitfenster: From recruitment to completion of intervention, up to 15 days.
Incidence of protocol deviation, indications for protocol deviation.
From recruitment to completion of intervention, up to 15 days.
Time for Delivery
Zeitfenster: From recruitment to completion of postpartum period, up to 6 months.
Amount of study team time needed for delivery.
From recruitment to completion of postpartum period, up to 6 months.
Financial Resources
Zeitfenster: From recruitment to postpartum period, up to 6 months.
Amount of monetary resources needed for study delivery.
From recruitment to postpartum period, up to 6 months.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Pregnancy Latency
Zeitfenster: From time of PPROM diagnosis (D0) until day of delivery, up to 3 months.
Number of days participants remain pregnant after PPROM until delivery
From time of PPROM diagnosis (D0) until day of delivery, up to 3 months.
Pregnancy Outcome
Zeitfenster: From time of PPROM diagnosis (D0) until day of delivery, up to 3 months.
Intrauterine fetal demise, neonatal demise while in NICU, living infant to NICU discharge.
From time of PPROM diagnosis (D0) until day of delivery, up to 3 months.
NICU Admission
Zeitfenster: From day of delivery through neonatal discharge, up to 4 months.
Requirement for NICU admission.
From day of delivery through neonatal discharge, up to 4 months.
Neonatal Ventilatory Support
Zeitfenster: From day of delivery through neonatal discharge, up to 4 months.
Level of ventilatory support required for neonate (none, bubble CPAP, intubation).
From day of delivery through neonatal discharge, up to 4 months.
Neonatal Sepsis
Zeitfenster: From day of delivery through neonatal discharge, up to 4 months.
Rates of early-onset sepsis, late-onset sepsis (including culture positive sepsis and culture-negative, clinically suspected sepsis)
From day of delivery through neonatal discharge, up to 4 months.
Neonatal Intraventricular Hemorrhage (IVH)
Zeitfenster: From day of delivery through neonatal discharge, up to 4 months.
Grade of IVH if present.
From day of delivery through neonatal discharge, up to 4 months.
Neonatal respiratory distress syndrome
Zeitfenster: From day of delivery through neonatal discharge, up to 4 months.
Documented respiratory distress syndrome by neonatology providers.
From day of delivery through neonatal discharge, up to 4 months.
Necrotizing enterocolitis
Zeitfenster: From day of delivery through neonatal discharge, up to 4 months.
Rate of documented necrotizing enterocolitis by neonatology team.
From day of delivery through neonatal discharge, up to 4 months.
Mode of delivery
Zeitfenster: From day of PPROM (D0) through day of delivery, up to 3 months.
Cesarean section, vaginal delivery, or operative delivery.
From day of PPROM (D0) through day of delivery, up to 3 months.
Indication for delivery
Zeitfenster: From day of PPROM (D0) through day of delivery, up to 3 months.
Non-reassuring fetal status, labor, intra-uterine infection, placental abruption, cord prolapse.
From day of PPROM (D0) through day of delivery, up to 3 months.
Maternal group B streptococcus status
Zeitfenster: From day of PPROM (D0) through day of delivery, up to 3 months.
Positive or negative group B streptococcus maternal rectovaginal culture.
From day of PPROM (D0) through day of delivery, up to 3 months.
Maternal postpartum hemorrhage
Zeitfenster: From day of PPROM (D0) through 6 weeks postpartum, up to 4 months.
Estimated blood loss greater than 1000mL after delivery.
From day of PPROM (D0) through 6 weeks postpartum, up to 4 months.
Suspected intraamniotic infection
Zeitfenster: From day of PPROM (D0) through day of delivery, up to 3 months.
Defined as maternal temperature greater than 39 degrees Celsius OR maternal temperature between 38.0-38.9 degrees Celsius plus one or more additional clinical risk factors: maternal leukocytosis greater than 15,000/mm^3, purulent cervical drainage, or fetal tachycardia.
From day of PPROM (D0) through day of delivery, up to 3 months.
Confirmed intraamniotic infection
Zeitfenster: From day of PPROM (D0) through delivery with postpartum placental pathology result, up to 3 months.
Positive amniotic fluid test result OR placental pathology demonstrating histologic evidence of infection or inflammation.
From day of PPROM (D0) through delivery with postpartum placental pathology result, up to 3 months.
Maternal sepsis
Zeitfenster: From day of PPROM (D0) through 6 weeks postpartum, up to 4 months.
Suspected sepsis documented by clinical provider in chart or culture proven sepsis.
From day of PPROM (D0) through 6 weeks postpartum, up to 4 months.
Maternal placental abruption
Zeitfenster: From day of PPROM (D0) through day of delivery, up to 3 months.
Clinical evidence of placental abruption documented by OBGYN provider.
From day of PPROM (D0) through day of delivery, up to 3 months.
Maternal ICU Admission
Zeitfenster: From day of PPROM (D0) through 6 weeks postpartum, up to 4 months.
Required admission to adult ICU prior to or after delivery.
From day of PPROM (D0) through 6 weeks postpartum, up to 4 months.
Maternal postpartum endomtritis
Zeitfenster: From day of delivery through 6 weeks postpartum.
Documented clinical diagnosis of endometritis in participant chart.
From day of delivery through 6 weeks postpartum.
Maternal retained products of conception
Zeitfenster: From day of delivery through 6 weeks postpartum.
Clinical documentation of retained products of conception in participant chart.
From day of delivery through 6 weeks postpartum.
Additional maternal surgical procedures
Zeitfenster: From day of delivery through 6 weeks postpartum.
Requirement of additional surgical procedures following delivery (suction dilation and curettage, hysterectomy).
From day of delivery through 6 weeks postpartum.
Maternal blood transfusion
Zeitfenster: From day of PPROM (D0) through 6 weeks postpartum, up to 4 months.
Documented maternal blood transfusion following delivery.
From day of PPROM (D0) through 6 weeks postpartum, up to 4 months.
Maternal antibiotic course completion
Zeitfenster: From day of PPROM (D0) through day of delivery, up to D14.
Number of participants in intervention arm who completed the extended antibiotic course.
From day of PPROM (D0) through day of delivery, up to D14.
Additional maternal antibiotic administration
Zeitfenster: From day of PPROM (D0) through day of delivery, up to 3 months.
Maternal antibiotics administered for other indications after enrollment in the study.
From day of PPROM (D0) through day of delivery, up to 3 months.
Maternal placental pathology
Zeitfenster: From day of PPROM (D0) through delivery with postpartum placental pathology result, up to 3 months.
Maternal and fetal inflammation stage/grade as defined by the Amsterdam Criteria.
From day of PPROM (D0) through delivery with postpartum placental pathology result, up to 3 months.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Alexa Henderson

Ermittler

  • Hauptermittler: Christina Megli, MD/PhD, University of Pittsburgh Magee-Womens Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Juli 2026

Primärer Abschluss (Geschätzt)

1. Mai 2028

Studienabschluss (Geschätzt)

1. Juli 2028

Studienanmeldedaten

Zuerst eingereicht

29. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Juni 2026

Zuerst gepostet (Tatsächlich)

25. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

25. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • STUDY25110085

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

All IPD collected throughout the study will potentially be shared with future collaborating sites if the feasibility trial is expanded to a multi-center trial.

IPD-Sharing-Zeitrahmen

Beginning 3 months after publication without end.

IPD-Sharing-Zugriffskriterien

Collaborating principal investigators will have access to IPD. The information will be shared upon request via secure email or to advance further research efforts in the case of a multi-site trial.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • ANALYTIC_CODE
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur PPROM

Klinische Studien zur Standard Azithromycin Dosing

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in United States

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren